ES2116918A1 - Medicamento para la administracion nasal. - Google Patents

Medicamento para la administracion nasal.

Info

Publication number
ES2116918A1
ES2116918A1 ES09601391A ES9601391A ES2116918A1 ES 2116918 A1 ES2116918 A1 ES 2116918A1 ES 09601391 A ES09601391 A ES 09601391A ES 9601391 A ES9601391 A ES 9601391A ES 2116918 A1 ES2116918 A1 ES 2116918A1
Authority
ES
Spain
Prior art keywords
nasal administration
medicaments
vaccine
medicament
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09601391A
Other languages
English (en)
Other versions
ES2116918B1 (es
Inventor
Yutaka Mizushima
Yasuo Kosaka
Kayoko Hosakawa
Ryozo Nagata
Megumu Higaki
Rie Igarashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTT Institute Co Ltd
Original Assignee
LTT Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTT Institute Co Ltd filed Critical LTT Institute Co Ltd
Publication of ES2116918A1 publication Critical patent/ES2116918A1/es
Application granted granted Critical
Publication of ES2116918B1 publication Critical patent/ES2116918B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MEDICAMENTO PARA LA ADMINISTRACION NASAL. COMPRENDE UNA VACUNA O UN PEPTIDO FARMACOLOGICAMENTE ACTIVO COMBINADOS CON UN POLVO DE RESINA DE INTERCAMBIO DE IONES CUYO TAMAÑO MEDIO DE PARTICULA NO ES MAYOR DE 200 UM. APLICABLE A LA PREVENCION Y AL TRATAMIENTO DE ENFERMEDADES.
ES09601391A 1995-07-12 1996-06-21 Medicamento para la administracion nasal. Expired - Fee Related ES2116918B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP07197919A JP3098401B2 (ja) 1995-07-12 1995-07-12 経鼻投与用製剤

Publications (2)

Publication Number Publication Date
ES2116918A1 true ES2116918A1 (es) 1998-07-16
ES2116918B1 ES2116918B1 (es) 1999-04-01

Family

ID=16382464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09601391A Expired - Fee Related ES2116918B1 (es) 1995-07-12 1996-06-21 Medicamento para la administracion nasal.

Country Status (11)

Country Link
US (1) US5942242A (es)
JP (1) JP3098401B2 (es)
KR (1) KR970005305A (es)
CN (1) CN1140609A (es)
AU (1) AU702108B2 (es)
CA (1) CA2180215A1 (es)
DE (1) DE19627392A1 (es)
ES (1) ES2116918B1 (es)
FR (1) FR2736547A1 (es)
GB (1) GB2303064B (es)
IT (1) IT1284049B1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126536A1 (es) * 1996-10-07 1999-03-16 Fuji Yakuhin Kogyo Kk "preparado farmaceutico para administracion intranasal"y procedimiento para su produccion.

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
CN1267220A (zh) * 1997-06-20 2000-09-20 大藏制药株式会社 凝胶化组合物
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US6651655B1 (en) * 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
CA2396381A1 (en) * 2000-01-20 2001-07-26 Akira Yanagawa Nasally administrable cyclic peptide compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6805857B2 (en) * 2000-03-06 2004-10-19 Kumarpal A. Shah Method of modulating factor D, factor H and CD4 cell immune response with a polystyrene sulfonate, alginate, and saline infusion solution
US20020106346A1 (en) * 2000-03-06 2002-08-08 Shah Kumarpal A. Immune modulation with polystyrene sulfonate
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co PHARMACEUTICAL COMPOSITIONS IN PARTICLE FORM
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
DE60318938T2 (de) 2002-03-20 2009-01-22 Mannkind Corp., Valencia Inhalationsgerät
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
JP2006522022A (ja) 2003-02-14 2006-09-28 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ プロテアソーム干渉に関連する避妊法および組成物
WO2004073729A1 (ja) * 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
ES2385934T3 (es) 2004-08-20 2012-08-03 Mannkind Corporation Catálisis de la síntesis de dicetopiperazina.
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
EP1824450B1 (en) * 2004-10-11 2012-11-14 Nasaleze Patents Limited Compositions for intranasal administration
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
JP2009508472A (ja) * 2005-08-11 2009-03-05 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 乾燥細胞形態のための方法および組成物
KR20160022404A (ko) 2005-09-14 2016-02-29 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
WO2008078730A1 (ja) 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
WO2009055740A2 (en) 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
KR101722802B1 (ko) 2009-09-16 2017-04-03 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 콜레라 및 장독소생성 이. 콜라이(ｅｔｅｃ) 설사에 대한 백신
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
EP2825106B1 (en) 2012-03-13 2019-05-08 Becton Dickinson France Injection device having a miniaturized drug delivery portion
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
PE20171334A1 (es) * 2015-02-17 2017-09-13 Lilly Co Eli Formulacion en polvo nasal para el tratamiento de hipoglicemia
CN106362158A (zh) * 2015-07-25 2017-02-01 于杰 增效药物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US11857566B2 (en) * 2018-12-03 2024-01-02 Uniwersytet Jagiellonski Sulfonated polystyrene derivative for use in the treatment and/or prophylaxis of cat flu
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
WO1990009780A1 (en) * 1989-02-25 1990-09-07 Danbiosyst Uk Limited Drug delivery compositions
EP0490806A2 (en) * 1990-09-20 1992-06-17 Sandoz Ltd. Nasal pharmaceutical compositions
EP0588255A1 (en) * 1992-09-12 1994-03-23 Dott Limited Company Physiologically active peptide compositions
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
JP2505430B2 (ja) * 1986-11-04 1996-06-12 帝人株式会社 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
JPS63115822A (ja) * 1986-11-04 1988-05-20 Teijin Ltd 生理活性ポリペプチド類の経鼻投与用粉末状組成物
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
ATE99543T1 (de) * 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5342922A (en) * 1989-03-08 1994-08-30 Washington University Inhibitors of retroviral protease
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
ES2159524T3 (es) * 1992-06-12 2001-10-16 Teijin Ltd Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
WO1990009780A1 (en) * 1989-02-25 1990-09-07 Danbiosyst Uk Limited Drug delivery compositions
EP0490806A2 (en) * 1990-09-20 1992-06-17 Sandoz Ltd. Nasal pharmaceutical compositions
EP0588255A1 (en) * 1992-09-12 1994-03-23 Dott Limited Company Physiologically active peptide compositions
WO1994027576A1 (en) * 1993-05-20 1994-12-08 Danbiosyst Uk Limited Nasal drug delivery composition containing nicotine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126536A1 (es) * 1996-10-07 1999-03-16 Fuji Yakuhin Kogyo Kk "preparado farmaceutico para administracion intranasal"y procedimiento para su produccion.

Also Published As

Publication number Publication date
JP3098401B2 (ja) 2000-10-16
GB2303064B (en) 1999-10-06
JPH0925238A (ja) 1997-01-28
GB9612841D0 (en) 1996-08-21
AU702108B2 (en) 1999-02-11
AU5945296A (en) 1997-01-23
US5942242A (en) 1999-08-24
CA2180215A1 (en) 1997-01-13
ES2116918B1 (es) 1999-04-01
CN1140609A (zh) 1997-01-22
IT1284049B1 (it) 1998-05-08
ITMI961261A1 (it) 1997-12-21
DE19627392A1 (de) 1997-01-16
KR970005305A (ko) 1997-02-19
GB2303064A (en) 1997-02-12
ITMI961261A0 (es) 1996-06-21
FR2736547A1 (fr) 1997-01-17

Similar Documents

Publication Publication Date Title
ES2116918A1 (es) Medicamento para la administracion nasal.
YU49279B (sh) Postupak za pripremanje farmaceutske formulacije za dobijanje leka za inhalacionu primenu
MXPA02008403A (es) Mejoras en o relacionadas con el suministro de farmacos por via oral.
NZ508526A (en) Opioid formulations for treating pain
GEP20043260B (en) Aerosolized Active Agent Delivery and Device for Realization Thereof
CA2041579A1 (en) Dosage form
GR900100659A (en) Dosage form for administering oral hupoglycemic glipizide
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2105165A1 (en) Dosage form for a delayed drug-delivery
DE3872635T2 (de) Pentamidin enthaltende pharmazeutische zusammensetzungen.
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
PL336658A1 (en) Stabilised tilbone compositions
MY124465A (en) Reduction of infarct volume using citicoline
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
GR3018930T3 (en) Slow-release medicament containing a dihydropyridine derivate as a nanosol and its preparation.
KR890003399A (ko) 약리적 활성 화합물 및 용도

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980716

Kind code of ref document: A1

Effective date: 19980716

PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20050622